Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Alnylam Pharmaceuticals's cash was $3.59B at Sep 30, 2026. For fiscal 2025 it was $2.91B, up 8.2% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $2.91B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.91B | +8.2% |
| FY2024 | Dec 31, 2024 | $2.69B | +10.7% |
| FY2023 | Dec 31, 2023 | $2.43B | +12.1% |
| FY2022 | Dec 31, 2022 | $2.17B | -8.6% |
| FY2021 | Dec 31, 2021 | $2.37B | +29.4% |
| FY2020 | Dec 31, 2020 | $1.83B | +20.4% |
| FY2019 | Dec 31, 2019 | $1.52B | +40.6% |
| FY2018 | Dec 31, 2018 | $1.08B | -35.9% |
| FY2017 | Dec 31, 2017 | $1.69B | +173.7% |
| FY2016 | Dec 31, 2016 | $617.80M | -40.0% |
| FY2015 | Dec 31, 2015 | $1.03B | +70.9% |
| FY2014 | Dec 31, 2014 | $602.11M | +144.9% |
| FY2013 | Dec 31, 2013 | $245.87M | +100.2% |
| FY2012 | Dec 31, 2012 | $122.81M | -16.1% |
| FY2011 | Dec 31, 2011 | $146.40M | -37.2% |
| FY2010 | Dec 31, 2010 | $233.13M | -17.2% |
| FY2009 | Dec 31, 2009 | $281.40M | +46.7% |
| FY2008 | Dec 31, 2008 | $191.79M | +82.4% |
| FY2007 | Dec 31, 2007 | $105.16M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.59B | +31.7% |
| Q2 FY2026 | Jun 30, 2026 | $3.31B | +15.8% |
| Q1 FY2026 | Mar 31, 2026 | $3.01B | +14.6% |
| Q4 FY2025 | Dec 31, 2025 | $2.91B | +8.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.72B | -1.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.86B | +9.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.63B | +11.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.69B | +10.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.77B | +15.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.61B | +28.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.36B | +15.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.43B | +12.1% |
| Q3 FY2023 | Sep 30, 2023 | $2.40B | +6.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.03B | -2.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.04B | -7.4% |
| Q4 FY2022 | Dec 31, 2022 | $2.17B | -8.6% |
| Q3 FY2022 | Sep 30, 2022 | $2.24B | -0.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.08B | +12.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.21B | +33.6% |
| Q4 FY2021 | Dec 31, 2021 | $2.37B | +29.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.26B | +26.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.85B | +0.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.65B | +26.7% |
| Q4 FY2020 | Dec 31, 2020 | $1.83B | +20.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.78B | +3.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.84B | -4.5% |
| Q1 FY2020 | Mar 31, 2020 | $1.30B | +4.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.52B | +40.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.72B | +40.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.93B | +34.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.24B | -20.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.08B | -35.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.22B | +28.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.44B | +55.5% |
| Q1 FY2018 | Mar 31, 2018 | $1.57B | +181.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.69B | +173.7% |
| Q3 FY2017 | Sep 30, 2017 | $948.29M | – |
| Q2 FY2017 | Jun 30, 2017 | $923.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $556.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $617.80M | – |
See a number that looks wrong?